EHA 2023: Focus on CLL
Study data showed a fixed 24-cycle regimen of acalabrutinib combined with obinutuzumab was effective in patients with CLL.
Patients with CLL who progressed on pirtobrutinib shared some genetic alterations, but none clearly predicted resistance.
Real-world venetoclax durations were in line with approved CLL regimens, but many patients failed the fixed-dosing schedule.
Preliminary data from EHA2023 suggested navtemadlin plus acalabrutinib had acceptable safety and promising activity in CLL.
Advertisement
Advertisement
